PROFESSOR PAUL W LADENSON PRESENTS KARO BIO’S EPROTIROME AT THE 80TH ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION

STOCKHOLM, SWEDEN, September 24, 2009. The Swedish biotech company Karo Bio (Reuters: KARO.ST) today announced that results from a clinical phase II study of the company’s thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.

The presentation will be made by Professor Paul W Ladenson from the Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, at the 80th Annual Meeting of the American Thyroid Association (ATA), held September 23-27, 2009, at the Breakers Hotel, Palm Beach, Florida, US. The presentation will take place on September 26, at 3:30 pm US Eastern Time (EST) / 9:30 pm Central European Time (CET). For more information, please contact: Per Olof Wallström, President and Chief Executive Officer Phone: +46 8 608 60 20 E-mail: p.o.wallstrom@karobio.se Erika Söderberg Johnson, Chief Financial Officer Phone: +46 8 608 60 27 E-mail: erika.soderberg.johnson@karobio.se Notes to editors About Eprotirome Karo Bio's eprotirome for treatment of dyslipidemia has successfully completed three phase II clinical trials, of which two were finalized in 2008. In these trials it was first demonstrated that eprotirome, when given on top of ongoing statin treatment to dyslipidemic patients, gave a profound and clinically meaningful lowering of several important risk factors for development of cardiovascular disease. The results are very encouraging since there is a need for combine statins with drugs that have a different mechanism of action in order to reach the desired LDL-cholesterol levels. The second study showed that eprotirome gives significant additive effects when combined with ezetimibe, a cholesterol absorption inhibitor drug commonly prescribed with statins. About Karo Bio Karo Bio is a drug discovery and development company specializing in endocrinology and targeting nuclear receptors as target proteins for the development of novel pharmaceuticals. The company has a project portfolio with innovative molecules that primarily target dyslipidemia, diabetes, inflammation, and women’s health. In these areas, there are significant market opportunities and a clear need for pharmaceuticals with new mechanisms of action. Karo Bio develops compounds aimed at treating broad patient populations up to clinical proof of concept before out-licensing. In therapeutic niche areas, Karo Bio has the capacity to bring selected compounds into late stage clinical development and, potentially, to the market. In addition to the proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases. Karo Bio is listed on NASDAQ OMX Stockholm since 1998 (Reuters: KARO.ST). This press release is also available online at: www.karobio.com and www.newsroom.cision.com